ClinicalTrials.gg
Active, not recruitingNCT06831994Updated May 29, 2026

Digital Implementation of the German S3 Clinical Practice Guideline for Multimorbidity

An interventional study of gp-multitool.de in Asthma Bronchiale, Breast Neoplasms and Coronary Disease, sponsored by Universitätsklinikum Hamburg-Eppendorf. Active, not recruiting at 1 site in Germany. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by Universitätsklinikum Hamburg-Eppendorf · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
659
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 678 studies in Breast Neoplasms with a site in Germany — 114 open to participants now, 196 under way, 81 of them phase 3. Breast Neoplasms · Germany.

Enrollment
147th of 580
659 · median 273
Started
2025
with 34 others
No phase
102 of 678
28 open now
Primary completion
2027-02
later than 76 of 195 live
Registered
633rd of 678
by date

Among the 678 studies in Breast Neoplasms with a site in Germany, this one is the 147th largest by enrollment of the 580 interventional ones that give a count, is one of 35 that started in 2025, is one of 102 with no phase, reaches primary completion later than 76 of the 195 other live ones, and was the 633rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

114 of the 678 studies in Breast Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

109 more — sign in →

All 114 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 678 studies in Breast Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

The web application gp-multitool.de is a digital tool for implementing the German S3 clinical practice guideline for multimorbidity of the German Society of General Practitioners and Family Physicians in primary care. The tool enhances evidence-based and patient-centered care by assessing and providing information relevant for the primary care of this patient group. This cluster-randomised clinical evaluation study examines the effectiveness of an intervention based on gp-multitool.de in general practitioner (GP) practices in Germany.

Read the detailed description

The web application gp-multitool.de study is a digital tool for implementing the German S3 clinical practice guideline for multimorbidity of the German Society of General Practitioners and Family Physicians in primary care. The tool enhances evidence-based and patient-centered care for patients with multimorbidity by assessing and providing information relevant for the primary care of this patient group. The study intervention is based on this digital tool and aims to reduce the probability of hospital admissions (primary outcome) and their outpatient health care use, and to improve process quality of care, patients' health-related quality of life, and patient satisfaction (secondary outcomes).

This cluster-randomized clinical evaluation study examines the effectiveness of the gp-multitool.de intervention in GP practices. GPs in the intervention group implement the intervention in consultations with participating patients for 12 months. Intervention GPs gain access to the digital tool, and get a brief introduction to its functionalities, a video tutorial, a written manual, and contact data of telephone support, which can be called in case of any technical or organizational problems in relation to the digital tool. In addition, they receive a short training in the intervention and a checklist of requirements defined in the study protocol. Moreover, each intervention practice will be provided with a mobile device, facilitating inclusion of patients without access to the internet. GPs in the control group receive no intervention and provide care as usual.

Patients will be recruited from GP practices in urban and rural administrative districts in Germany. The evaluation study is based on telephone interviews of patients and their GPs. Practices will be randomized after the baseline assessment by an independent statistician who does not have access to the assessed patient and practice data. The primary outcome will be analyzed using a multilevel mixed-effects logistic regression model, and secondary outcomes will be analyzed by multilevel mixed-effects linear and negative-binomial regression models. The project staff conducting patient interviews will be blinded regarding allocation of the patient's practices.

03

Conditions studied

  • Asthma Bronchiale
  • Breast Neoplasms
  • Coronary Disease
  • Diabetes Mellitus, Type 2
  • Diabetes Mellitus, Type 1
  • Pulmonary Disease, Chronic Obstructive
  • Obesity
  • Heart Failure
  • Chronic Low-back Pain
  • Depression
  • Osteoporosis
  • Rheumatoid Arthritis
  • Comorbidities and Coexisting Conditions
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • participation in a disease management program (DMP); in Germany, DMPs have been implemented in outpatient care for asthma, breast neoplasms, coronary heart disease, diabetes mellitus type 1, diabetes mellitus type 2, , obesity, heart failure, chronic low back pain, depression, osteoporosis, rheumatoid arthritis
  • at least two of the following coexisting conditions: Hypertension, Lipid metabolism disorders, Chronic low back pain, Severe vision reduction, Joint arthrosis, Diabetes mellitus, Chronic ischemic heart disease, Thyroid dysfunction, Cardiac arrhythmias, Obesity, Hyperuricemia/Gout, Prostatic hyperplasia, Lower limb varicosis, Liver diseases, Depression, Asthma/Chronic obstructive pulmonary disease, Gynaecological problems, Atherosclerosis/Peripheral arterial occlusive disease, Osteoporosis, Renal insufficiency, Cerebral ischemia/Chronic stroke, Cardiac insufficiency, Severe hearing loss, Chronic cholecystitis/Gallstones, Somatoform disorders, Hemorrhoids, Intestinal diverticulosis, Rheumatoid arthritis/Chronic polyarthritis, Cardiac valve disorders, Neuropathies, Dizziness, Dementias, Urinary incontinence, Urinary tract calculi, Anemias, Anxiety, Psoriasis, Migraine/chronic headache, Parkinson's disease, Cancers, Allergies, Chronic gastritis/Gastroesophageal reflux disease, Sexual dysfunction, Insomnia, Tobacco abuse, Hypotension

Exclusion criteria

Exclusion Criteria:

  • no capacity to consent
  • functional limitations precluding participation in the intervention (eg, loss of vision)
  • functional limitations precluding participation in telephone interviews (eg, loss of hearing)
  • limited German language skills precluding participation in telephone interviews
  • participation in other trials during the observation time of the evaluation study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
659 participants (actual)

Study arms

  • No intervention
    Control group

    Care as usual

  • Experimental
    Intervention group

    GPs in the intervention arm have to use the web application gp-multitool.de. For every participating patient they have to use at least four specific questionnaires in the first six intervention months, i.e. 1a is required, and either 2a or 2b, and either 3a or 3b, and either 4a or 4b or 4c. In the following six intervention months, GPs in the intervention arm also have to use at least four specific questionnaires, i.e., 1a is required again, and either 2a or 2b, and either 3a or 3b, and either 4a or 4b or 4c. Results from the questionnaires need to be discussed between GPs and patients. Additionally, at least one medication review during the first six intervention months is obligatory.

    Other: gp-multitool.de

Interventions

  • Othergp-multitool.de

    The intervention is based on the digital tool gp-multitool.de. The GPs can send questionnaires by email to patients and patients can fill out questionnaires at their home or in the waiting room of the practice using any digital device with browser and access to the internet. The digital tool also includes instructions for conducting a medication review. Results will be available from the computers of attending GPs. Decisions from talks between GPs and patients can be documented in the tool. The tool includes ten questionnaires: 1. patient preferences (including a. treatment goals, and b. involvement of other persons in decision making); 2. social life (including a. activities and participation, and b. social support); 3. treatment situation (including a. problems with medication, and b. treatment burden); 4. health complaints (including a. pain, b. psychiatric disorders, and c. other complaints). 5. resilience and protective behavior against heat.

06

What researchers measure

Primary outcomes

  1. Whether patients have stayed at least once for at least one night in hospital during the preceding twelve months

    The outcome will be assessed by a standardised questionnaire. The patients will be asked how often they had been in hospital during the preceding twelve months and how long these stays had lasted. Before analysis, the outcome will be dichotomised.

    Time frame: Once at baseline (before randomization of practices) and once at follow-up (immediately after the intervention)

Secondary outcomes

  1. The number of contacts with the GP during the preceding twelve months

    The outcome will be assessed by asking the patients how often they had visited their GP during the preceding twelve months.

    Time frame: Once at baseline (before randomization of practices) and once at follow-up (immediately after the intervention)

  2. The number of contacts with outpatient specialists during the preceding twelve months

    The outcome will be assessed by asking the patients how often they had visited outpatient specialists during the preceding twelve months.

    Time frame: Once at baseline (before randomization of practices) and once at follow-up (immediately after the intervention)

  3. Quality of care as assessed by the summary score of the "GP-reported core set of quality indicators for older adults with multimorbidity in primary care" during the preceding twelve months

    The outcome will be assessed by the "GP-reported core set of quality indicators for older adults with multimorbidity in primary care" (Schäfer I et al. 2023, digital object identifier (DOI): https://doi.org/10.1186/s12916-023-02856-0), which has a possible range between 0 and 12 points. Higher scores indicate a better quality of primary care.

    Time frame: Once at baseline (before randomization of practices) and once at follow-up (immediately after the intervention)

  4. Quality of care as assessed by the summary score of the "patient-reported core set of quality indicators for older adults with multimorbidity in primary care" during the preceding twelve months

    The outcome will be assessed by the "Patient-reported core set of quality indicators for older adults with multimorbidity in primary care" (Schäfer I et al. 2023, DOI: https://doi.org/10.1186/s12916-023-02856-0), which has a possible range between 0 and 7 points. Higher scores indicate a better quality of primary care.

    Time frame: Once at baseline (before randomization of practices) and once at follow-up (immediately after the intervention)

  5. Self-rated health as assessed by the EuroQoL visual analogue scale

    The outcome will be assessed by the EuroQoL visual analogue scale (Herdman M et al. 2011, DOI: 10.1007/s11136-011-9903-x), which has a possible range between 0 and 100 points. Higher scores indicate a better self-rated health.

    Time frame: Once at baseline (before randomization of practices) and once at follow-up (immediately after the intervention)

  6. Health-related quality of life as assessed by the "Short-Form-Health Survey (SF-12)" questionnaire

    The outcome will be assessed by the "Short-Form-Health Survey (SF-12)" questionnaire (Wirtz M.A. et al. 2018, DOI: 10.1026/0012-1924/a000205), which has a possible range between 0 and 100 points. Higher scores indicate a better health-related quality of life.

    Time frame: Once at baseline (before randomization of practices) and once at follow-up (immediately after the intervention)

  7. Patient satisfaction with chronic illness care assessed by the "Patient Assessment of Chronic Illness Care (PACIC 5A)" questionnaire

    The outcome will be assessed by the "PACIC 5A" questionnaire (Rosemann T et al. 2007, DOI: 10.1111/j.1365-2753.2007.00786.x), which has a possible range between 1 and 5 points. Higher scores indicate a higher patient satisfaction with chronic illness care from patient's perspective.

    Time frame: Once at baseline (before randomization of practices) and once at follow-up (immediately after the intervention)

07

Study locations

1 site
08

References and documents

Publications

  • Schafer I, Menzel A, Lezius S, Krause L, Zapf A, Luhmann D, Scherer M, Paucke V, Nothacker J. Effects of a digital tool implementing the German S3 clinical practice guideline for multimorbidity in primary care (gp-multitool.de): study protocol for a cluster-randomised controlled trial. BMJ Open. 2025 Aug 3;15(8):e102086. doi: 10.1136/bmjopen-2025-102086. PubMed 40754332 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data will be included in the publication as supplementary file.

Supporting information: Study protocol, Informed consent form, Analytic code

Time frame: Data will be made available at the time of publication. No time limit is planned.

Access criteria: No restrictions.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Feb 2027, 24 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 24 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2025
First posted
Feb 18, 2025
StartActual
Feb 26, 2025
Primary completionEst.
Feb 28, 2027
CompletionEst.
Feb 28, 2027
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06831994
Responsible party
Sponsor
First posted
Feb 18, 2025
Start date
Feb 26, 2025
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
May 29, 2026

Study contacts

Ingmar Schäfer, Dr.
principal investigator · Universitätsklinikum Hamburg-Eppendorf

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion